Quintiles named preferred provider by neglected diseases consortium
Quintiles spokesman Phil Bridges told Outsourcing-pharma.com that as a preferred provider Quintiles “We will be able to provide a full range of drug development services.”
He also said that members of the 14-strong consortium of product development partnerships (PDP) will be able to use Quintiles extensive range of drug development services for a discounted rate.
Bridges told the WRAL tech wire that: “There is a potential for quite a bit of business. We also will be able to have an impact on areas that are the focus of the group.”
The PDPs, which a not-for-profit entities, are expected to undertake as many as 128 clinical trials over the next two years, with development focusing on treatments for neglected diseases such as HIV, malaria and tuberculosis.
The group is part funded by the Bill and Melinda Foundation’s $10bn commitment to foster development of treatments for neglected diseases, as well as various government bodies and private entities.
In a press statement Kelly McKee, Quintiles VP of public health and government services, said: “The work [the consortium is] doing has the potential to reshape global health within a generation.
“The public health issues on which they are focused has the potential to save millions of lives. We are very excited to be named a preferred provider to the consortium and look forward to helping advance this critical mission.”
